atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT assetProactive Investors • 04/17/24
atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyGlobeNewsWire • 04/17/24
atai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalystsProactive Investors • 04/15/24
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.Zacks Investment Research • 04/04/24
atai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapiesProactive Investors • 03/28/24
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsGlobeNewsWire • 03/28/24
atai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studyProactive Investors • 03/27/24
atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionGlobeNewsWire • 03/27/24
atai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulationProactive Investors • 03/04/24
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01GlobeNewsWire • 03/04/24
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/28/24
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionInvestorPlace • 01/09/24
atai Life Sciences expands its pipeline with $50M investment in Beckley PsytechProactive Investors • 01/05/24
Psychedelic firm atai Life Sciences expands its pipeline with $50M investment in Beckley PsytechProactive Investors • 01/04/24
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsGlobeNewsWire • 01/04/24
Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash ValueSeeking Alpha • 11/29/23
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsGlobeNewsWire • 11/14/23
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitGlobeNewsWire • 10/06/23
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsGlobeNewsWire • 10/02/23
Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentumProactive Investors • 09/15/23